Prescribing information

 

Please note that the black triangle (▼) and associated additional monitoring activities required for Kisqali®, only applies to its marketing authorisation in Great Britain. It is NOT applicable to the marketing authorisation of Kisqali® in Northern Ireland.

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

The patient case study videos were developed and funded by Novartis Pharmaceuticals Ltd and are intended for UK healthcare professionals only.

Welcome to our patient case study series – a collection of videos where leading oncologists share clinical experiences of using KISQALI as a first-line treatment. By detailing individual patient characteristics, diagnoses and outcomes, these videos are designed to support treatment best practice. 

Interact with the map below to view location specific case studies.

HR+, hormone receptor-positive; HER2−, human epidermal growth factor receptor 2-negative.

Rate this content: 
Average: 4 (1 vote)
UK | July 2022 | 221927
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]